OTCPK:ATHX.Q 収益、費用、利益 ( )USD Millions
日付	収益	収益	G+A経費	研究開発費
30 Sep 23	0	-38	10	0
30 Jun 23	0	-47	10	0
31 Mar 23	2	-58	13	0
31 Dec 22	5	-73	15	0
30 Sep 22	6	-81	19	0
30 Jun 22	11	-84	19	-35
31 Mar 22	8	-83	18	0
31 Dec 21	6	-87	20	0
30 Sep 21	6	-87	19	0
30 Jun 21	1	-94	19	35
31 Mar 21	1	-90	19	0
31 Dec 20	1	-79	16	0
30 Sep 20	0	-66	14	0
30 Jun 20	0	-56	13	0
31 Mar 20	4	-47	12	0
31 Dec 19	6	-45	11	0
30 Sep 19	7	-46	12	0
30 Jun 19	10	-44	11	0
31 Mar 19	25	-27	11	0
31 Dec 18	24	-24	10	0
30 Sep 18	24	-26	10	0
30 Jun 18	22	-24	9	0
31 Mar 18	3	-37	9	0
31 Dec 17	4	-32	8	0
30 Sep 17	4	-26	8	0
30 Jun 17	3	-25	8	0
31 Mar 17	3	-26	8	0
31 Dec 16	17	-15	8	0
30 Sep 16	27	-5	8	0
30 Jun 16	27	-5	8	0
31 Mar 16	27	1	8	0
31 Dec 15	12	-16	8	0
30 Sep 15	2	-27	7	0
30 Jun 15	1	-25	7	0
31 Mar 15	2	-23	7	0
31 Dec 14	2	-22	7	0
30 Sep 14	2	-25	7	0
30 Jun 14	3	-26	7	0
31 Mar 14	3	-33	6	0
31 Dec 13	2	-31	6	0
30 Sep 13	4	-24	6	4

質の高い収益: ATHX.Qは現在利益が出ていません。

利益率の向上: ATHX.Qは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: ATHX.Qは利益が出ておらず、過去 5 年間で損失は年間12.5%の割合で増加しています。

成長の加速: ATHX.Qの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ATHX.Qは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -14.4% ) と比較することは困難です。

株主資本利益率

高いROE: ATHX.Qの負債は資産を上回っているため、自己資本利益率を計算することは困難です。

Athersys 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Recent updates

Motion for Case Conversion Filed by Athersys, Inc.

Healios K.K. (TSE:4593) completed the acquisition of Substantially all assets of Abt Holding Company, Advanced Biotherapeutics, Inc, Athersys, Inc. (OTCPK:ATHX.Q), ReGenesys BVBA and ReGenesys, LLC .

Athersys, Inc. announced delayed annual 10-K filing

Motion for Joint Administration Filed by Athersys, Inc.

Athersys, Inc. Announces Termination of Daniel A. Camardo as Chief Executive Officer, Effective from December 31, 2023

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc.(OTCPK:ATHX) dropped from S&P TMI Index

Athersys, Inc. Receives A Delisting Determination Letter from Nasdaq

Athersys, Inc. Reports Interim Analysis Results of MASTERS-2 Clinical Study with Multistem in Ischemic Stroke

Athersys, Inc. Appoints Jane Wasman as Board Chair

Athersys, Inc. has completed a Follow-on Equity Offering in the amount of $3.5 million.

Athersys, Inc. announced delayed 10-Q filing

Athersys, Inc. Appoints Neema Mayhugh to Its Board of Directors, Nominations, Governance and Compliance Committee, Compensation Committee and Audit Committee

New major risk - Market cap size

Athersys Receives Written Notice from Nasdaq Regarding Non-Compliance with Minimum Closing Bid Price Requirement

Athersys, Inc., Annual General Meeting, Sep 27, 2023

Athersys, Inc. Announces Patient Enrollment Begins in Third and Final Cohort of the Phase 2 Matrics-1 Clinical Study Evaluating Athersys' Multistem Following Hemorrhagic Trauma

Athersys Granted Clinical Type B Meeting with FDA for Masters-2 Clinical Trial Protocol Discussion

Athersys, Inc. Provides an Update on Ongoing Clinical Trials with MultiStem for the Treatment of Patients Following Hemorrhagic Trauma (MATRICS-1) and for the Treatment of Ischemic Stroke (MASTERS-2)

Athersys, Inc. Appoints Joseph Nolan to Its Board of Directors

Athersys Receives A Written Notice from Nasdaq Regarding Bid Price Requirement

CEO, Secretary recently bought US$55k worth of stock

Athersys, Inc. to Report Q3, 2022 Results on Nov 15, 2022

Athersys, Inc. Announces the Resignation of Kenneth H. Traub from the Board of Directors

Athersys Receives Non-Compliance Letter from Nasdaq

Athersys: Is Big Pharma Sleeping At The Wheel?

Athersys extends exercise period of warrants in connection with recent offering

Athersys announces 1-for-25 reverse stock split

One Analyst's Revenue Estimates For Athersys, Inc. (NASDAQ:ATHX) Are Surging Higher

Athersys stock falls ~9% after reporting Q2 loss, fall in cash and cash equivalents

Athersys, Inc. Announces Favorable Preclinical Results for MultiStem Treatment in Defense Department Radiation Countermeasure Study

Athersys, Inc. Appoints Kasey Rosado as Interim Chief Financial Officer

Kasey Rosado named interim CFO of Athersys

Athersys, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Athersys: Dead Man Walking

Athersys, Inc. Designates Dan Camardo as the Principal Financial Officer and Principal Accounting Officer

Athersys, Inc. Announces Board Changes

Athersys, Inc. Announces Management Changes

Athersys, Inc., Annual General Meeting, Jun 15, 2022

Consensus forecasts updated

Athersys: Focus On Stroke

Athersys, Inc. to Report Q1, 2022 Results on May 06, 2022

Price target decreased to US$3.33

Athersys - Hero Or Zero Opportunity

Consensus revenue estimates fall by 70%

Price target decreased to US$3.33

Consensus forecasts updated

Price target increased to US$5.00

Athersys, Inc. to Report Q4, 2021 Results on Mar 15, 2022

Athersys, Inc. to Present an Outlook of its Ischemic Stroke Program Including Perspectives on the Upcoming TREASURE Study Data Readout

Athersys: Near-Term Progress In Stem Cell Phase 3 Trials Could Multiply Shares In 2022

Here's Why Athersys (NASDAQ:ATHX) Must Use Its Cash Wisely

Athersys, Inc. Announces Manuscript Reporting Data from the Company’s Must-ARDS Clinical Trial

Athersys: COVID-ARDS Is The Company's Most Important Target

Price target decreased to US$3.75

Third quarter 2021 earnings released: US$0.071 loss per share (vs US$0.11 loss in 3Q 2020)

Price target decreased to US$4.67

Athersys Shares Are Ready To Rumble Following Period Of Turmoil

Consensus forecasts updated

Consensus forecasts updated

Athersys: Subgroup Analysis As A Masterstroke

New Publication Provides Further Clarity of MultiStem's Mechanism of Action on Modulating the Inflammatory Response in Critical Care Indications

Athersys, Inc. announced that it expects to receive $100 million in funding from Aspire Capital Partners, LLC

Here's Why We're Watching Athersys' (NASDAQ:ATHX) Cash Burn Situation

Consensus revenue estimates fall to US$9.42m

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.29 loss in FY 2019)

Athersys, Inc. to Report Fiscal Year 2020 Results on Mar 25, 2021

Is Athersys (NASDAQ:ATHX) In A Good Position To Invest In Growth?

Athersys, Inc. Announces Chief Executive Officer Changes

過去基準チェック /06